Articles and Monographs
We recommend Federation of State Medical Board`s (FSMB), Responsible Opioid Prescribing: A Physician's Guide. Click this link to learn more.
FAIR USE NOTICE: The literature listed below may be copyrighted material, and the use of it on Paindr.com may not have been specifically authorized by the copyright owner. Such material is made available on a non-profit basis for educational and discussion purposes only. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in 17 USC § 107. For more information go to: http://www.law.cornell.edu
Fudin J, McCarberg BH, Pasternak G, Schechter LN, Schnoll SH, Lande SD. Pharmacist perspective on extended release analgesics for persistent pain. Pharmacy Today. 13(10):54–68. October 2007.
Hegstad S, Khiabani HZ, Oiestad EL, Berg T, Christophersen AS. Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. Journal of Analytical Toxicology, Vol.31, may 2007.
Arnold LM, ,Goldenberg DL,Stanford SB,Lalonde JK,Sandhu HS, Keck PE, Welge JA,Bishop F,Stanford KE,Hess EV,Hudson JI. Gabapentin in the Treatment of Fibromyalgia. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Vol. 56. No. 4. April 2007. pp 1331-1344.
Prommer Eric. Levorphanol: the forgotten opioid. Support Care Cancer (2007) 15:259-264.
Ciero TJ, Inciardi JA, Woody GE, Shnoll S, Munoz A. The Development of a Comprehensive Risk-Management Program for Prescription Opioid Analgesics: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®). PAIN MEDICINE 2007. Vol. 8, No 2, Pg 157-170.
Raymo LL, Camejo M, Fudin J. Eradicating analgesic use of meperidine in a hospital. AJHP pp. 1150-1153. June 1, 2007. Am J Health-Syst Pharm—Vol 64 Jun 1, 2007. (For duplication requests, e-mail Dr. Fudin or see Medscape version now.)
Kerns Robert D. Research on pain and pain management in Veterans Health Administration: Promoting improved pain
care for veterans through science and scholarship. Journal of Rehabilitation Research & Development. Volume 44, Number 2, 2007.
Kaloyanides KB, McCabe SE, Cranford JA, Teter CJ. Prevalence of Illicit Use and Abuse of Prescription Stimulants, Alcohol, and Other Drugs Among College Students: Relationship with Age at Initiation of Prescription Stimulants. Pharmacotherapy 2007;27(5):666–674.
Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians. A Scientific Statement From the American Heart Association. Circulation. 2007;115.
Ballantyne Jane C. Opioids for Chronic Nonterminal Pain. South Med J. 2006;99(11):1245-1255.
Wilcox MC, Allison J, Benzuly K, Borum M, Cryer B, Tilo G, Hunt R, Ladabaum U, Lanus A, Paulus H, Regueiro C, Sandler RS, Simon L. Consensus Development Conference on the Use of Nonsteroidal Anti-Inflammatory Agents, Including Cyclooxygenase-2 Enzyme Inhibitors and Aspirin. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1082–1089.
Sumapa Chaiamnuay, Jeroan J. Allison, and Jeffrey R. Curtis. Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs. Am. J. Health Syst. Pharm., Oct 2006; 63: 1837 - 1851.
International Expert Advisory Group Report on Palliative Care. Marymount Hospice and Atlantic Philanthropies.
Click here to view Systematic Review of Intrathecal Pump Therapy
Impact of Prescription Monitoring Programs on Prescription Patterns and Indicators of Opioid Abuse. This is a PDF slide file, courtesy of Dr. Robert Twillman. Dr. Tillman is a psychologist at the University of Kansas School of Medicine. [Click here for the PDF file].
Reissig JE, and Rybarczyk AM. Pharmacologic Treatment of Opioid Induced Sedation in Chronic Pain. Ann. Pharmacother., Apr 2005; 39: 727–731.
Krantz MJ, Lowery CM, Martell BA, Gourevitch MN, Arnsten JH. Effects of Methadone on QT-Interval Dispersion. Pharmacotherapy 2005;25(11):1523–1529.
Florete, OG. Urinary drug testing in pain management. Practical Pain Management. April 2005. Pg 35-42.
Probes, LM. Opioid blood levels in chronic pain management. Practical Pain Management. April 2005. Pg 35-42. P 12-18.
Fudin J, Levasseur DJ, Passik SD, Kirsh KL, Coleman J. Chronic pain management with opioids in patients with past or current substance abuse problems. Journal of Pharmacy Practice. 2003, 16;4:291-308.
Clause S, Fudin J, Mergner A, Lutz JL, Kavanaugh MM, Fessler K, Chirumamilla S. Prescribing privileges among pharmacists in veterans affairs medical centers. Am J Health-syst Pharm. Vol.58, June 15, 2001, pp. 1143-1145.
July 2006: The availability of websites offering to sell opioid medications without prescriptions. Forman RF, Woody GE, McLellan T, Lnch KG. Am J Psychiatry 2006; 163:1233-1238.
Endo Receives FDA Approval For Opana(R) ER (oxymorphone HCl) Extended-Release And Opana(R) (oxymorphone HCl) Immediate Release Tablets CII. Click here for article.
Kral LA, Leavitt SB. (MR: Fudin J.) Opioid Tapering. Safely Discontinuing Opioid Analgesics. Pain Treatment Topix. pp.1-7, March 2006.
March 2006: Chronic Pain in Veterans, A Profile of Patients in a VA Pain Clinic. Drake D, Beckworth W, Brown R, McNeary l, Cifu D, Kim D. March 2006. Federal Practitioner. Pages 15-22.
March-April 2006: Opioid Analgesics in Primary Care: Challanges and New Advances in the Management of Noncancer Pain. Sinatra Raymond. J Am Board Fam Med. 2006;19:165-77.
February 28, 2006: [PROPOXYPHENE] Pain drug too deadly, group says. By Robert Davis, USA TODAY.
January 6, 2006: The Big Chill - Inserting DEA in to End of Life Care. New England Journal of Medicine. Quill TE, Meier DE.
Cupp MJ, Tracy TS. Cytochrome P450:new nomenclature and clinical applications. American Family Physician. Jan. 1, 1998. Pages 107-116.
Virani A, Mailis A, Shapiro LE, Shear NH. Drug interactions in human neuropathic pain pharmacology. Pain. 73:1997:3-13.
Reder RF, Oshlack B, Miotto JB, Benziger DD, Kaiko RF. Steady-state bioavailability of controlled-release oxycodone in normal subjects. Clinical Therapeutics. Vol. 18, No. 1, 1996. Page 95-105.